On Dec. 23, 2020, Altimmune announced that the FDA had issued a clinical hold on the Companyﾒs Investigational New Drug (IND) application for AdCOVID, a single-dose intranasal COVID-19 vaccine candidate.

The Agency requested certain protocol modifications and the submission of additional Chemistry, Manufacturing and Controls data.